By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Bristol-Myers Squibb Company 

345 Park Avenue

New York  New York  10154  U.S.A.
Phone: 212-546-4000 Fax: 212-546-4020


SEARCH JOBS


Key Statistics


Email:
Ownership: Public

Web Site: Bristol-Myers Squibb
Employees:
Symbol: BMY
 





Collaborations

Gilead 

PanVera LLC 

Pharmagene Laboratories Limited 

Johnson & Johnson 

Amersham Biosciences 

Lexicon Genetics Incorporated 

Athersys, Inc.  Athersys will provide Bristol-Myers Squibb with cell lines expressing validated drug targets produced using the RAGE-Validated Target technology. BMS plans to use its combinatorial chemistry capabilities to develop small molecule drug candidates against the validated targets.

Merck & Co.  Diabetes

Affinimark Technologies Inc. 

GlaxoSmithKline (North Carolina) 

Medarex, Inc. 

Gilead (Durham, NC) 

Phyton Biotech, Inc.  - Cancer

Gilead (Seattle, WA) 





Company News
Bristol-Myers Squibb (BMY) Grabs Record Fast Approval for Opdivo 3/5/2015 6:34:48 AM
Bristol-Myers Squibb (BMY) Bets $975 Million on Bavarian Nordic (BAVA.CO)'s Prostate Cancer Vaccine 3/4/2015 5:34:00 AM
Bristol-Myers Squibb (BMY) Announces Dividend 3/3/2015 8:55:54 AM
Bristol-Myers Squibb (BMY) Release: U.S. FDA Accepts Biologics Licensing Application For Opdivo (Nivolumab) For The Treatment Of Advancedsquamous Non-Small Cell Lung Cancer 3/2/2015 11:46:20 AM
Bristol-Myers Squibb (BMY) Release: ALLY Trial Demonstrates 97% Hepatitis C Cure Rates Among Patients Coinfected With HIV After Ribavirin-Free Investigational 12-Week Regimen Of Daclatasvir And Sofosbuvir 2/27/2015 10:54:46 AM
Bristol-Myers Squibb (BMY) Release: Study Of Next-Generation Investigational HIV-1 Maturation Inhibitor Shows Positive Results In Preventing Viral Replication Via Different Mechanism Of Action Than Current Therapies 2/26/2015 11:17:38 AM
Regen BioPharma Comments On Dcellvax Cancer IDO-Targeting Technology In Relation To Bristol-Myers Squibb (BMY)-Flexus Biosciences Announcement 2/25/2015 1:54:57 PM
Bristol-Myers Squibb (BMY) Release: 48-Week Analysis Of Investigational HIV-1 Attachment Inhibitor Paves Way For Phase III Trial Initiation 2/25/2015 10:40:35 AM
Jacobs Awarded Contract From Bristol-Myers Squibb (BMY) 2/24/2015 12:28:39 PM
Bristol-Myers Squibb (BMY)To Present At Cowen and Company Annual Global Health Care Conference 2/24/2015 11:17:22 AM
12345678910...
//-->